Kynurenine 3-Monooxygenase Inhibition in Blood Ameliorates Neurodegeneration

被引：441

作者：

Zwilling, Daniel ^{[1
]}

Huang, Shao-Yi ^{[1
,4
,5
]}

Sathyasaikumar, Korrapati V. ^{[6
]}

Notarangelo, Francesca M. ^{[6
]}

Guidetti, Paolo ^{[6
]}

Wu, Hui-Qiu ^{[6
]}

Lee, Jason ^{[1
]}

Truong, Jennifer ^{[1
]}

Andrews-Zwilling, Yaisa ^{[1
]}

Hsieh, Eric W. ^{[1
]}

Louie, Jamie Y. ^{[1
]}

Wu, Tiffany ^{[1
]}

Scearce-Levie, Kimberly ^{[1
]}

Patrick, Christina ^{[7
]}

Adame, Anthony ^{[7
]}

Giorgini, Flaviano ^{[8
]}

Moussaoui, Saliha ^{[9
]}

Laue, Grit ^{[9
]}

Rassoulpour, Arash ^{[10
]}

Flik, Gunnar ^{[10
]}

Huang, Yadong ^{[1
]}

Muchowski, Joseph M. ^{[1
]}

Masliah, Eliezer ^{[7
]}

Schwarcz, Robert ^{[6
]}

Muchowski, Paul J. ^{[1
,2
,3
,4
,5
]}

机构：

[1] Univ Calif San Francisco, Gladstone Inst Neurol Dis, San Francisco, CA 94158 USA

[2] Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94158 USA

[3] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94158 USA

[4] Taube Koret Ctr Huntingtons Dis Res, San Francisco, CA 94158 USA

[5] Hellman Family Fdn Program Alzheimers Dis Res, San Francisco, CA 94158 USA

[6] Univ Maryland, Maryland Psychiat Res Ctr, Sch Med, Baltimore, MD 21228 USA

[7] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA

[8] Univ Leicester, Dept Genet, Leicester LE1 7RH, Leics, England

[9] Novartis Inst BioMed Res, CH-4002 Basel, Switzerland

[10] Brains On Line BV, NL-9713 AV Groningen, Netherlands

来源：

CELL | 2011年 / 145卷 / 06期

基金：

美国国家卫生研究院;

关键词：

QUINOLINIC ACID; MOUSE MODEL; TRYPTOPHAN-METABOLISM; ALZHEIMERS-DISEASE; GLUTAMATE UPTAKE; PATHWAY; EXPRESSION; AMINOTRANSFERASE; NEUROTOXICITY; INFLAMMATION;

D O I：

10.1016/j.cell.2011.05.020

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

070307 [化学生物学]; 071010 [生物化学与分子生物学];

摘要：

Metabolites in the kynurenine pathway, generated by tryptophan degradation, are thought to play an important role in neurodegenerative disorders, including Alzheimer's and Huntington's diseases. In these disorders, glutamate receptor-mediated excitotoxicity and free radical formation have been correlated with decreased levels of the neuroprotective metabolite kynurenic acid. Here, we describe the synthesis and characterization of JM6, a smallmolecule prodrug inhibitor of kynurenine 3-monooxygenase (KMO). Chronic oral administration of JM6 inhibits KMO in the blood, increasing kynurenic acid levels and reducing extracellular glutamate in the brain. In a transgenic mouse model of Alzheimer's disease, JM6 prevents spatial memory deficits, anxiety-related behavior, and synaptic loss. JM6 also extends life span, prevents synaptic loss, and decreases microglial activation in a mouse model of Huntington's disease. These findings support a critical link between tryptophan metabolism in the blood and neurodegeneration, and they provide a foundation for treatment of neurodegenerative diseases.

引用

页码：863 / 874

页数：12

共 54 条

[21]

Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice [J].

Guidetti, Paolo ;

Bates, Gillian P. ;

Graham, Rona K. ;

Hayden, Michael R. ;

Leavitt, Blair R. ;

MacDonald, Marcy E. ;

Slow, Elizabeth J. ;

Wheeler, Vanessa C. ;

Woodman, Ben ;

Schwarcz, Robert .

NEUROBIOLOGY OF DISEASE, 2006, 23 (01) :190-197

[22]

Kynurenine and its metabolites in Alzheimer's disease patients [J].

Gulaj, E. ;

Pawlak, K. ;

Bien, B. ;

Pawlak, D. .

ADVANCES IN MEDICAL SCIENCES, 2010, 55 (02) :204-211

[23]

Many Neuronal and Behavioral Impairments in Transgenic Mouse Models of Alzheimer's Disease Are Independent of Caspase Cleavage of the Amyloid Precursor Protein [J].

Harris, Julie A. ;

Devidze, Nino ;

Halabisky, Brian ;

Lo, Iris ;

Thwin, Myo T. ;

Yu, Gui-Qiu ;

Bredesen, Dale E. ;

Masliah, Eliezer ;

Mucke, Lennart .

JOURNAL OF NEUROSCIENCE, 2010, 30 (01) :372-381

[24]

QUINOLINIC ACID AND KYNURENINE PATHWAY METABOLISM IN INFLAMMATORY AND NONINFLAMMATORY NEUROLOGICAL DISEASE [J].

HEYES, MP ;

SAITO, K ;

CROWLEY, JS ;

DAVIS, LE ;

DEMITRACK, MA ;

DER, M ;

DILLING, LA ;

ELIA, J ;

KRUESI, MJP ;

LACKNER, A ;

LARSEN, SA ;

LEE, K ;

LEONARD, HL ;

MARKEY, SP ;

MARTIN, A ;

MILSTEIN, S ;

MOURADIAN, MM ;

PRANZATELLI, MR ;

QUEARRY, BJ ;

SALAZAR, A ;

SMITH, M ;

STRAUSS, SE ;

SUNDERLAND, T ;

SWEDO, SW ;

TOURTELLOTTE, WW .

BRAIN, 1992, 115 :1249-1273

[25]

HUMAN MACROPHAGES CONVERT L-TRYPTOPHAN INTO THE NEUROTOXIN QUINOLINIC ACID [J].

HEYES, MP ;

SAITO, K ;

MARKEY, SP .

BIOCHEMICAL JOURNAL, 1992, 283 :633-635

[26]

The brain metabolite kynurenic acid inhibits α7 nicotinic receptor activity and increases non-α7 nicotinic receptor expression:: Physiopathological implications [J].

Hilmas, C ;

Pereira, EFR ;

Alkondon, M ;

Rassoulpour, A ;

Schwarcz, R ;

Albuquerque, EX .

JOURNAL OF NEUROSCIENCE, 2001, 21 (19) :7463-7473

[27]

Environmental enrichment slows disease progression in R61/2 Huntington's disease mice [J].

Hockly, E ;

Cordery, PM ;

Woodman, B ;

Mahal, A ;

van Dellen, A ;

Blakemore, C ;

Lewis, CM ;

Hannan, AJ ;

Bates, GP .

ANNALS OF NEUROLOGY, 2002, 51 (02) :235-242

[28]

A GLYCINE SITE ASSOCIATED WITH N-METHYL-D-ASPARTIC ACID RECEPTORS - CHARACTERIZATION AND IDENTIFICATION OF A NEW CLASS OF ANTAGONISTS [J].

KESSLER, M ;

TERRAMANI, T ;

LYNCH, G ;

BAUDRY, M .

JOURNAL OF NEUROCHEMISTRY, 1989, 52 (04) :1319-1328

[29]

Impaired glutamate uptake in the R6 Huntington's disease transgenic mice [J].

Liévens, JC ;

Woodman, B ;

Mahal, A ;

Spasic-Boscovic, O ;

Samuel, D ;

Goff, LKL ;

Bates, GP .

NEUROBIOLOGY OF DISEASE, 2001, 8 (05) :807-821

[30]

Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice [J].

Mangiarini, L ;

Sathasivam, K ;

Seller, M ;

Cozens, B ;

Harper, A ;

Hetherington, C ;

Lawton, M ;

Trottier, Y ;

Lehrach, H ;

Davies, SW ;

Bates, GP .

CELL, 1996, 87 (03) :493-506

← 1 2 3 4 5 6 →